Bristol-Myers Squibb Co vs Charter Communications Inc — how do they compare? Bristol-Myers Squibb Co trades at $63.41 (market cap $129.94B), while Charter Communications Inc trades at $156.98 (market cap $18.81B). The key difference: Bristol-Myers Squibb Co is far larger — about 6.9× Charter Communications Inc's market cap, and Bristol-Myers Squibb Co pays a 3.96% dividend while Charter Communications Inc pays none. Which is the better fit depends on your goals.
| BMY | CHTR | |
|---|---|---|
Market Cap | $129.94B | $18.81B |
Sector | Health | Media |
52-Week High | $65.89 | $282.74 |
52-Week Low | $42.60 | $123.31 |
Enterprise Value | $163.92B | $115.01B |
Dividend Yield | 3.96% | — |
Trailing returns across standard periods
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →Charter is the product of the 2016 merger of three cable companies, each with a decades-long history in the business: Legacy Charter, Time Warner Cable, and Bright House Networks. The firm now holds networks capable of providing television, internet access, and phone services to roughly 54 million U.S. homes and businesses, around 40% of the country. Across this footprint, Charter serves 29 million residential and 2 million commercial customer accounts under the Spectrum brand, making it the second-largest U.S. cable company behind Comcast. The firm also owns, in whole or in part, sports and news networks, including Spectrum SportsNet (long-term local rights to Los Angeles Lakers games), SportsNet LA (Los Angeles Dodgers), SportsNet New York (New York Mets), and Spectrum News NY1.
Read more on CHTR →